STING1 and melanoma: The aim of this study was to evaluate whether the combination of immunotherapy activating the cGAS-STING pathway with the anti-vascular agent RGD-(KLAKLAK)2 will result in a better anti-tumor response in tumors with low level of STING protein (4T1 breast carcinoma) compared to tumors with high STING expression (B16-F10 melanoma).